What the FDA labels say about taking them together
Irinotecan and rolapitant
Rolapitant's FDA label of August 19, 2020 names irinotecan in its drug interactions section; the irinotecan labels PlainMeds reads (2) do not name rolapitant. The rolapitant label: “Increased plasma concentrations of BCRP substrates may result in potential adverse reactions.”
Check it at the source: the irinotecan FDA label on DailyMed (effective May 12, 2026, Pharmacia & Upjohn Company LLC); the rolapitant FDA label on DailyMed (effective August 19, 2020, TerSera Therapeutics LLC).
What does the irinotecan label say about rolapitant?
Irinotecan's label (effective May 12, 2026) and its 1 other brand-application label do not name rolapitant in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Camptosar), NDA020571 (Pfizer Inc), as published by Pharmacia & Upjohn Company LLC, effective May 12, 2026 (SPL set e518dfc6-7e93-4fee-a66c-51e1ab71c056), via openFDA; the full label on DailyMed
What does the rolapitant label say about irinotecan?
Rolapitant label, drug interactionsClinical Impact: Increased plasma concentrations of BCRP substrates (…) may result in potential adverse reactions. Intervention: Monitor for adverse reactions related to the concomitant drug if use of VARUBI cannot be avoided. Use the lowest effective dose of rosuvastatin (see prescribing information for additional information on recommended dosing).
Source: FDA drug label (Varubi), TerSera Therapeutics LLC, effective August 19, 2020 (SPL set a52896cd-4a98-49b8-82db-bf1985a64d97), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Irinotecan | Rolapitant | |
|---|---|---|
| Labeled for | Colorectal cancer | n/a |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | n/a | n/a |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once